Characteristics and results of studies reporting the effect of terlipressin in patients with cirrhosis and type-1 HRS
| Author, year (reference) | Type of study | Success rate of therapy† | Dose (mg/day) | Duration (days) | Survival at 4 weeks* | Adverse events |
|---|---|---|---|---|---|---|
| C, case report; R, retrospective; PU, prospective uncontrolled; PC, prospective controlled; RCT, randomised controlled trial; ND, not determined. | ||||||
| *Success rate of therapy means partial or complete response in terms of renal function. T+A, terlipressin+albumin; T, terlipressin; P, placebo; A, albumin. | ||||||
| †Survival was reported at 60 days. | ||||||
| Ganne-Carrie, 199677 | C | 1/1 | 2 | 67 | Yes | Yes |
| Le Moine, 199878 | C | 1/1 | 6 | 30 | Yes | No |
| Duhamel, 200079 | R | 6/12 | 2–6 | 3–10 | 9/18 | 4/12 |
| Colle, 200280 | R | 11/18 | 2.8 (0.1) | 9 (1) | 1/16 | 0/18 |
| Halimi, 200281 | R | 12/16 | 1.5–12 | 2–16 | 3/7 | 4/16 |
| Moreau, 200247 | R | 53/99 | 3.2 (1.2) | 11 (12) | 37/99 | 23/99 |
| Danalioglu, 200382 | R | 3/7 | 2–4 | 3–14 | ND | No |
| Uriz, 200048 | PU | 4/6 | 3–6 | 5–15 | 4/6 | 1/6 |
| Mulkay, 200183 | PU | 12/12 | 1–6 | 8–14 | 3/12 | 4/12 |
| Angeli, 200684 | PU | 12/19 | 2–12 | ⩽15 | 13/19 | ND |
| Ortega, 200249 | PU | T+A: 8/9 | 2 | 4–14 | 8/9 | 1/16 |
| T: 1/7 | 1/7 | |||||
| Hadengue, 199838 | RCT | 6/9 | 2 | 2 | ND | 0/9 |
| Solanki, 200352 | RCT | T: 5/12 | 2 | 14 | nd | 5/12 |
| P: 0/12 | ||||||
| Sanyal, 200653 | RCT | T+A: 19/56 | 4–8 | 14 | 27/56† | |
| A: 7/56 | 27/56† | |||||
| Total | 154/284 | 2–12 | 3–67 | 108/251 | 43/209 | |